FDA approves Zepbound as first weight-loss drug for obstructive sleep apnea

The FDA has approved Zepbound, the first prescription drug for obstructive sleep apnea, specifically for people with obesity. This weight-loss medication is part of a class known as GLP-1 receptor agonists and is intended to be used alongside diet and exercise. Zepbound was previously approved for weight loss in November 2023. The new approval may help some patients gain insurance coverage under Medicare, which currently does not cover weight-loss drugs unless used for other health conditions. Clinical trials showed significant improvements in sleep apnea symptoms and weight loss among participants using Zepbound. Patients experienced fewer breathing disruptions and lost an average of 18% to 20% of their body weight over a year.